Racing Ahead in China's BCI Market
China's brain-computer interface (BCI) race just got a turbo boost, with Gestala sprinting out of the starting blocks at breakneck speed. After launching on January 1, 2026, the company has already pulled in a whopping RMB 570 million—around US$84 million—across two funding rounds in six short months. But what really has investors buzzing is their interest in Gestala's angle: moving beyond traditional electrode-based BCIs toward less invasive and more comprehensive approaches.
The Brains Behind Gestala
Co-founders Phoenix Peng and Tianqiao Chen bring a well-honed pedigree to this venture. With roots in the Shanda Group and deep ties to brain-inspired intelligence from Fudan University, they aren't novices in neuroscience or business. Their combined expertise lays a strong foundation for a startup that isn't just raising capital, but also quickly building capabilities in research, ultrasound engineering, medical-device manufacturing, clinical trials, and artificial intelligence.
Beyond Electrodes: The Move to Ultrasound
Peng's prior endeavors, including NeuroXess, showcased invasive electrode technology's potential. But with Gestala, the aim is broader and much bolder—leveraging ultrasound to cover larger brain areas and interact with deep neural circuits. Why settle for reading minor local neural activity when you can aim for the grand picture, concerning memory, emotion, and planning?
Electrodes have their place, but ultrasound lets you have eyes on the whole battlefield. With functional ultrasound observing cerebral blood flows and focused ultrasonics potentially acting on specific brain sections, Gestala has big ambitions. But the trek to turn these visions into clinical solutions won't be simple. It's a heavy lift, requiring AI's growing might to transform scanner blips into actionable brain data.
A Stretched Timeline: Vision vs. Reality
Here's the kicker: While Gestala's got aspirations for a comprehensive brain platform, that'll read—and perhaps tweak—brain activities, it's a far cry from today's tech landscape. Current units can spot hemodynamic shifts tied to neurotransmission but still fall short of full readouts of neural firings.
Skulls—darn resilient—that scatter and distort acoustic waves add another layer of complexity. And yet, the company's bound and determined, setting sights on chronic pain as the proving ground. Tackling other conditions from depression to stroke rehab is on the horizon too.
"Brain-computer interfaces, ultrasound, artificial intelligence and life sciences are all different paths toward understanding human intelligence," shared Peng. "Our true subject of study is human intelligence itself."
Building a Global Blueprint
Gestala's no one-trick pony, though. Beginnings in Chengdu encompass product development and engineering, while Shanghai handles research and collaborations. They're eyeing overseas terrain too, contemplating a third headquarters in either Singapore or Hong Kong. Such ambitions aim to plug Gestala into international research nerve centers, nurturing talent flow and capitalizing on broader industry synergies.
The Road Forward: Testing the Waters
Despite securing impressive funding, Gestala's ultimate challenge lies ahead: transforming sophisticated risk into real-world rewards. Testing will unfold on three pivotal fronts: engineering, clinical and AI. The consistent targeting of brain regions across diverse skull configurations, ensuring treatments' safety and efficacy, and demonstrating the AI model's ability to connect a tangled web of data into coherent insight—all are steps they must take.
Let's be real—having capital won't alone secure Gestala's front-row status in the BCI saga. Only verifiable and reproducible clinical outcomes can show meaningful patient benefits. And turning the complex interplay of multimodal brain data into an intelligible, generalizable model—that's the litmus test for crossing milestones from concept to clinic.
A Glimpse of the Future in AI and Neuroscience
Gestala hopes to do more than just make a splash; it wants to rewrite the narrative of intelligence, connecting neuroscience's ancient truths with AI's groundbreaking possibilities. Through this lens, where understanding leads to creation, Gestala aims to bridge neuroscience and AI.
